Clinical trials
Lymphoma clinical trials
Cancer of the lymphatic system, part of the body’s immune defenses. We’re tracking 1,332 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06730542RecruitingPhase 1
Zanubrutinib plus pola-R-CHP and high-dose methotrexate for secondary CNS lymphoma
This trial tests a combination of targeted therapy (zanubrutinib) plus a standard chemo-immunotherapy regimen (pola-R-CHP) and high-dose methotrexate for people whose large B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this approach can effectively treat lymphoma in both the body and the central nervous system.
Miami, FloridaAges 18 years+ - NCT06708897RecruitingPhase 1
Study of lonitoclax for returning B-cell blood cancers
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Louisville, KentuckyAges 18 years+ - NCT04099966RecruitingPhase 2
Stem cell transplant to treat high-risk blood cancers
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
Valhalla, New YorkAges 1 day–30 years - NCT06696846RecruitingPhase 1
CAR-NK cell therapy for T cell lymphoma and acute myeloid leukemia
This trial tests an immune cell treatment (CAR-NK cells) targeting a protein called CD70 found on cancer cells. It's for people with T cell lymphoma or acute myeloid leukemia that has come back or not responded to other treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06698822RecruitingPhase 2
Tofacitinib cream for early-stage cutaneous T-cell lymphoma
This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.
Houston, TexasAges 18 years+ - NCT06687772RecruitingPhase 2
Preventing brain relapse in high-risk lymphoma with stem cell transplant
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
St Louis, MissouriAges 18–75 - NCT06530550RecruitingPhase 2
PI3K inhibitor for relapsed T/NK-cell lymphoma
This trial tests a targeted therapy called a PI3K inhibitor for people whose T-cell or NK-cell lymphoma has returned or not improved after other treatments. It aims to see if the drug can shrink or control the lymphoma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06665490Enrolling by invitation
Skin care wash study for mycosis fungoides
This study tests whether a special skin care body wash can improve skin lesions in people with mycosis fungoides, a type of skin lymphoma. Researchers will look at skin bacteria before and after using the wash.
Chicago, IllinoisAges 18–89 - NCT06219356RecruitingPhase 1
Study of GLB-002 for relapsed or refractory non-Hodgkin lymphoma
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06446128RecruitingEarly Phase 1
CAR-T cell therapy for B-cell lymphoma that returned or didn't respond
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06630091RecruitingPhase 2
Golidocitinib for newly diagnosed peripheral T-cell lymphoma
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
Houston, TexasAges 18 years+ - NCT05607420RecruitingPhase 1/Phase 2
Testing a new cell therapy for relapsed lymphoma with CD20/CD22
This Phase 1/2 trial studies UCART20x22, a lab-made cell therapy, for people with certain types of relapsed or treatment-resistant B-cell non-Hodgkin lymphoma (NHL). It may help by targeting lymphoma cells that carry CD20 and/or CD22 markers and then testing safety and early effectiveness.
Chicago, IllinoisAges 18–80 - NCT06610344Recruiting
BHB supplement with CAR-T for lymphoma
This study looks at adding a supplement called beta-hydroxybutyrate (BHB) to standard CAR-T therapy for people with large B-cell lymphoma. It may help improve how well the treatment works.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06607549RecruitingPhase 1
Targeted drug combo after focused radiation for CNS lymphoma
This trial tests a combination of two targeted drugs (loncastuximab tesirine and rituximab) given after focused radiation (SRS) for people with CNS lymphoma that has come back or not responded to treatment, or who cannot get standard high-dose methotrexate. The goal is to see if this approach is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06588478RecruitingPhase 2
Study of pirtobrutinib for CLL or SLL
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
Chandler, ArizonaAges 18 years+ - NCT06588868Recruiting
Systemic treatments for cutaneous T-cell lymphoma
This trial looks at the results of different systemic (whole-body) treatments for cutaneous T-cell lymphoma (CTCL), a rare type of lymphoma that affects the skin. It aims to understand how well these therapies work and help guide future treatment choices.
AnconaAges 18 years+ - NCT06594939RecruitingPhase 2
Combination chemo for elderly DLBCL patients
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
Milwaukee, WisconsinAges 70 years+ - NCT06594640RecruitingPhase 1/Phase 2
R-CMOP for newly diagnosed diffuse large B-cell lymphoma
This trial tests a new combination of drugs (R-CMOP) for people who have just been diagnosed with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) and have not yet received any treatment for it. The goal is to see if this treatment works well and is safe.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06572618RecruitingPhase 2
Nemtabrutinib plus rituximab for first-line mantle cell lymphoma
This trial tests a new combination of two drugs, nemtabrutinib (a targeted pill) and rituximab (an antibody infusion), for people with mantle cell lymphoma (MCL) who haven't had prior treatment. The goal is to see how well these drugs work together to control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT06569680RecruitingPhase 2
Mosunetuzumab for untreated extranodal marginal zone lymphoma
This trial tests a new drug called mosunetuzumab for people with a type of slow-growing lymphoma (extranodal marginal zone lymphoma) that has not been treated before. The goal is to see if the drug helps shrink the lymphoma and control the disease.
Miami, FloridaAges 18 years+ - NCT06583083RecruitingPhase 2
Sintilimab plus chemo vs chemo alone for advanced ENKTL lymphoma
This trial tests whether adding the immunotherapy drug sintilimab to a standard chemotherapy regimen (P-GEMOX) works better than chemotherapy alone for people with advanced ENKTL lymphoma. The goal is to see if the combination improves outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT06570447RecruitingPhase 2
Glofitamab and chidamide for relapsed or refractory DLBCL
This trial tests a combination of two drugs, glofitamab and chidamide, for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded after at least two prior treatments. The goal is to see if this combination can help when other options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06580002RecruitingPhase 2
Can Riluzole Help with Chemo Brain? A Pilot Study
This study tests if a medicine called riluzole (currently used for ALS) can help with 'chemo brain' – memory and thinking problems after cancer treatment. It is for people who feel their mental sharpness has declined after breast cancer therapy, certain chemotherapies, or brain radiation.
Orange, CaliforniaAges 18 years+ - NCT06549595RecruitingPhase 3
Testing a new drug combo for untreated follicular lymphoma
This study tests a new combination of two drugs (surovatamig and rituximab) for people with follicular lymphoma who have not been treated before. The goal is to see if this combination works better than standard treatments.
Huntsville, AlabamaAges 18–130
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma?
- Yes. Clin2 currently lists 1,332 recruiting lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.